INVA

ANALYST NOTE: INNOVIVA, INC. (INVA) DATE: 2026-06-13 CURRENT PRICE: $22.49

1. Structural Readiness

• Conservative Entry: — (Pending confirmed breakout above the coil resistance).
• Aggressive/Pre-Breakout Entry: — (Not actionable on its own; forming coils are partial signals).
• Breakout Level: — (Not yet defined; requires price to close above the coil resistance).
• Current Price: $22.49.
• Extension: — (No extension data provided relative to the breakout level).
• ATR Context: Current ATR is 2.8% (productive). This sits within the historical "sweet spot" (4–6% is ideal, but 2.8% indicates moderate volatility suitable for sizing, provided the setup confirms).
• Pivot Strength: — (Not quantified in current data).
• Cap Bucket: Small.
• Sector: Healthcare.

2. Thesis Layer

• Thesis Classification: TACTICAL / SETUP-LED.
• Analysis: As of 2026-06-13, there is no named macro or secular thesis attached to this name in the current evidence base. The investment case is not driven by a broad thematic shift (e.g., "AI in Pharma" or "Global Antibiotic Crisis") but rather by the specific structural quality of the chart setup combined with the underlying business fundamentals.

3. Business Analysis

Innoviva, Inc. operates as a pharmaceutical company with a dual-engine business model: a high-margin royalty portfolio and a commercial operating platform for critical care and infectious diseases.

• Royalty Portfolio (Respiratory):
• The company holds significant royalty rights from Glaxo Group Limited (GSK) on key respiratory assets.
• Assets: RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol) and ANORO ELLIPTA (umeclidinium bromide/vilanterol).
• Terms: Under the LABA Collaboration Agreement, Innoviva receives 15% on the first $3.0 billion of annual global net sales of RELVAR/BREO, and 5% on sales above that threshold. ANORO royalties tier upward from 6.5% to 10%.
• Historical Context: As of the 2018 earnings transcript, these products were outperforming the market significantly (BREO up 77% YoY vs. 4% market growth).
• Current Status (2026): As of the May 6, 2026, SEC filing, the royalty portfolio remains the core asset, with net sales of RELVAR/BREO recorded at $405.3 million in Q4 2017, showing 48% growth. The 2026 filings confirm the continued existence of these agreements and the royalty structure.

• Commercial Operating Platform (Critical Care & Infectious Disease):
• Portfolio: Anchored by four commercial and marketed products.
• New Launch: The company holds an FDA-approved product, NUZOLVENCE (formerly zoliflodacin), approved on December 12, 2025, for the treatment of uncomplicated urogenital gonorrhea.
• Market Expectation: Management stated in the May 6, 2026, filing that NUZOLVENCE is "expected to be available to patients in the second half of 2026."
• Strategic Assets: The company holds a significant stake in Armata Pharmaceuticals, a leader in bacteriophage development.
• Thesis Drivers: The platform addresses immediate global health threats, including *N. gonorrhoeae* (82.4 million cases globally in 2020) and multidrug-resistant *Acinetobacter*.

• Financial Health:
• Royalty Revenue: Net of amortization, royalty revenue is a key line item.
• Margins: Historically, the company achieved a 91% EBITDA margin in 2017 due to the royalty model.
• Forward Estimates: The financial spine indicates a forward consensus EPS of $3.574 for FY1 and $2.2575 for FY2.

4. Archetype and Conviction

• Archetype: Growth Leader (with elements of a Margin Inflector).
• *Fit:* The company fits the "Growth Leader" archetype due to the successful commercialization of new assets (NUZOLVENCE) and the high-margin, scalable nature of its royalty business. The transition from a development-stage biotech to a commercial entity with a new FDA-approved product in 2025/2026 supports this classification.
• Valuation Context:
• The forward consensus EPS of $3.574 (FY1) suggests the market is pricing in significant earnings growth.
• At a price of $22.49, the stock trades at approximately 6.3x forward FY1 EPS. This valuation implies the market is pricing in the successful ramp-up of NUZOLVENCE and continued royalty growth, but the "Small" cap bucket suggests potential for rerating if execution is flawless.
• Conviction Stack:
• Thesis Strength: Low (Tactical only; no macro tailwind).
• Evidence Quality: High (Strong historical data on royalties; clear FDA approval and launch timeline for NUZOLVENCE).
• Rerating Potential: Moderate to High (Dependent on NUZOLVENCE commercial uptake and royalty stability).

5. Invalidations, Strengths, and Gaps

• What Would Invalidate:
• Failure of NUZOLVENCE to launch or gain traction in the second half of 2026, or regulatory setbacks regarding the product.
• A significant deterioration in GSK's sales of BREO/ANORO, which would directly impact Innoviva's royalty revenue.
• What Would Strengthen:
• A confirmed breakout above the coil resistance level (price closing above the defined breakout level).
• Positive commercial data or early sales reports for NUZOLVENCE in H2 2026.
• Upward revisions to the forward consensus EPS (currently $3.574).
• Gaps in Evidence:
• Breakout Level: The specific resistance level required for a confirmed breakout is not defined.
• 2026 Financials: While forward EPS is provided, specific 2026 revenue breakdowns for NUZOLVENCE are not yet available (as it is expected to launch in H2 2026).
• ATR at Breakout: The structural quality ATR at the moment of breakout is not yet known.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: FDA approval of NUZOLVENCE (Dec 2025) with H2 2026 launch; High-margin royalty model with GSK on BREO/ANORO; Forward consensus EPS of $3.574 for FY1. Key risks: Setup is only "Forming" (not confirmed breakout); No named secular thesis to drive momentum; Dependence on single new product launch (NUZOLVENCE) for growth; Small cap volatility. Sizing hint: Position size should be conservative given the "Forming" status and lack of confirmed breakout; treat as a partial conviction play. Expected path: Management expects NUZOLVENCE to become available to patients in H2 2026; if sales ramp as expected, the stock may re-rate higher, potentially triggering a breakout from the current coil structure. Expected horizon: 6 to 12 months (aligned with NUZOLVENCE commercial ramp and potential breakout confirmation).